FEBUGET-40 MG contains febuxostat, a selective xanthine oxidase inhibitor. Xanthine oxidase is involved in the conversion of hypoxanthine and xanthine into uric acid. By inhibiting this enzyme, febuxostat reduces uric acid production and lowers serum uric acid levels.
The medication is used for long-term management of hyperuricemia in patients with gout. It is intended for urate-lowering therapy rather than for immediate relief of an acute gout attack.
Who may be recommended this medication:
Research and clinical evidence:
Febuxostat is used for the long-term management of hyperuricemia in patients with gout.
The main treatment goal is to reduce serum uric acid and prevent complications associated with prolonged hyperuricemia, including urate crystal formation, tophi, and recurrent gout attacks.
Febuxostat works by inhibiting xanthine oxidase, an enzyme involved in the final stages of uric acid production. This reduces the formation of uric acid.
Febuxostat is not intended for the immediate treatment of an acute gout flare. Gout flares may temporarily become more frequent when urate-lowering therapy is initiated, so a healthcare professional may prescribe additional anti-inflammatory prophylaxis.
Febuxostat is taken orally, usually once daily, with or without food. The dose and duration of treatment should be determined by a healthcare professional based on serum uric acid levels, clinical condition, comorbidities, and treatment response. Regular monitoring of serum uric acid is recommended. Do not change the dose or discontinue treatment without medical advice.
Seek urgent medical attention if severe skin reactions, swelling of the face or throat, difficulty breathing, chest pain, sudden weakness, or other serious symptoms occur.
